fda glp-1 compounding enforcement news october 2025 GLP-1s in 2026: What Brokers Need to Know FDA sets tirzepatide compounding deadlines

GLP-1 medications were originally developed to treat type 2 diabetes and are now commonly used for weight and metabolic management

This allows the body to adjust to the GLP-1 effects through a low dose that minimizes gastrointestinal side effects

Earlier this summer , we shared our first peptide update after the FDA announced that its Pharmacy Compounding Advisory Committee, known as PCAC, would meet on July 23 and 24, 2026

In a meta-regression analysis of 18 CVOTs, including 8 with GLP-1RAs, a significant association between HbA1c reduction and major adverse cardiovascular events (including cardiovascular mortality, non-fatal myocardial infarction [MI], heart failure, and non-fatal stroke) was shown

Cagnacci A, Barattini DF, Casolati E, Pecoroni A, Mangrella M, Patrascu LC

Consider initial therapy at this stage when glycated hemoglobin (HbA1C) 9% ( 75 mmol/mol)